Amgen announced positive top-line results from a pivotal Phase III head-to-head trial evaluating denosumab administered subcutaneously versus Zometa administered as an intravenous (IV) infusion in the treatment of bone metastases in 1,776 advanced cancer patients with solid tumors (not including breast and prostate cancer) or multiple myeloma. Here’s what Amgen had to say: “For the primary endpoint, patients treated with denosumab experienced a similar time to first skeletal-relat...